Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)

NCT01485796 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT01485796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01485796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Lead sponsor
Baxalta now part of Shire
Phase
Phase 2/3
Overall status
Completed
Start date
December 29, 2011
Completion date
January 1, 2013
Enrollment
54 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency diseases (pid)